CLINICAL STUDY

Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians

Shweta Varshney*, Sanjay Kumar Bhadada*, Uma Nahar Saikia¹, Naresh Sachdeva, Arunanshu Behera², Ashutosh Kumar Arya, Sadhna Sharma³, Anil Bhansali, Ambrish Mithal⁴ and Sudhaker D Rao⁵

Department of Endocrinology, Postgraduate Institute of Medical Education and Research, 4th Floor, F-Block, Room No. 2, Chandigarh 160012, India, Departments of ¹Histopathology, ²General Surgery and ³Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India, ⁴Medanta – The Medicity Hospital, Gurgaon, India and ⁵Bone and Mineral Research Laboratory, Henry Ford Hospital, Detroit, Michigan, USA

(Correspondence should be addressed to S K Bhadada; Email: bhadadask@rediffmail.com)

*(S Varshney and S K Bhadada contributed equally to this work)

Abstract

Background: To explore underlying molecular mechanisms in the pathogenesis of symptomatic sporadic primary hyperparathyroidism (PHPT).

Materials and methods: Forty-one parathyroid adenomas from patients with symptomatic PHPT and ten normal parathyroid glands either from patients with PHPT (n = 3) or from euthyroid patients without PHPT during thyroid surgery (n = 7) were analyzed for vitamin D receptor (VDR), calcium-sensing receptor (CASR), cyclin D1 (CD1), and parathyroid hormone (PTH) expressions. The protein expressions were assessed semiquantitatively by immunohistochemistry, based on percentage of positive cells and staining intensity, and confirmed by quantitative real-time PCR.

Results: Immunohistochemistry revealed significant reductions in VDR (both nuclear and cytoplasmic) and CASR expressions and significant increases in CD1 and PTH expressions in adenomatous compared with normal parathyroid tissue. Consistent with immunohistochemistry findings, both VDR and CASR mRNAs were reduced by 0.36- and 0.45-fold change (P < 0.001) and CD1 and PTH mRNAs were increased by 9.4- and 17.4-fold change respectively (P < 0.001) in adenomatous parathyroid tissue. PTH mRNA correlated with plasma PTH (r = 0.864, P < 0.001), but not with adenoma weight, while CD1 mRNA correlated with adenoma weight (r = 0.715, P < 0.001). There were no correlations between VDR and CASR mRNA levels and serum Ca, plasma intact PTH, or 25-hydroxyvitamin D levels. In addition, there was no relationship between the decreases in VDR and CASR mRNA expressions and the increases in PTH and CD1 mRNA expressions.

Conclusions: The expression of both VDR and CASR are reduced in symptomatic PHPT in Asian Indians. In addition, CD1 expression was greatly increased and correlated with adenoma weight, implying a potential role for CD1 in adenoma growth and differential clinical expression of PHPT.

European Journal of Endocrinology 169 109–116

Introduction

Primary hyperparathyroidism (PHPT) is a common sporadic endocrine disorder characterized by hypercalcemia with non-suppressed or elevated parathyroid hormone (PTH) levels. A single parathyroid adenoma is the most common cause of PHPT (1), but the pathogenesis of these lesions is poorly understood. Altered calcium-sensing receptor (CASR)-mediated control of PTH secretion with the consequent increased parathyroid cell proliferation is fundamental to the development of PHPT (2, 3). In addition, 1,25-dihydroxyvitamin D, through its interactions with vitamin D receptor (VDR) in parathyroid cells, modulates parathyroid function and growth (4, 5, 6, 7, 8).

Thus, both VDR and CASR play critical roles in the regulation of PTH synthesis and secretion, parathyroid cell proliferation, and maintenance of plasma calcium levels. Tumor-specific DNA rearrangements in a subset of parathyroid adenomas have shown overexpression of cyclin D1 (CD1) leading to increasing mitotic rate and parathyroid adenoma development (9, 10, 11).

Abnormalities in VDR (12, 13, 14), CASR (14, 15, 16, 17, 18), and CD1 (19, 20, 21, 22, 23) expression have been reported in the cases probably having mild form of PHPT, parathyroid cancers, and renal secondary hyperparathyroidism. However, very little is known about such abnormalities in adenomas from patients with symptomatic sporadic PHPT (24, 25, 26). Presentation of PHPT in Asian Indian is symptomatic...
Unlike the mostly asymptomatic nature of presentation in the West (24), accordingly, we examined the expression of VDR, CASR, CD1, and PTH using immunohistochemistry and confirmed with mRNA analyses in a cohort of parathyroid adenomas from Asian Indian patients with symptomatic PHPT.

**Materials and methods**

**Patient description and tissue collection**

The study was conducted at the Post Graduate Institute of Medical Education and Research (Chandigarh, India) from January 2008 to December 2010. After approval by the Institutional Ethics Committee, informed written consent was obtained from each patient. The diagnosis of PHPT was confirmed in each patient by the presence of hypercalcemia and elevated PTH levels and verified at surgery. Patients with parathyroid hyperplasia, secondary hyperparathyroidism, and multiple endocrine neoplasia syndromes were excluded.

Histopathologically confirmed parathyroid adenomas \( n = 41 \) were collected immediately in RNA-Later and stored at \(-80^\circ\text{C}\) until isolation of total RNA. Paraffin blocks of each tumor were retrieved from the Department of Histopathology. Normal parathyroid tissue \( n = 10 \) was obtained either from PHPT patients \( n = 3 \) or from patients undergoing thyroid surgery for euthyroid goiters in whom parathyroid gland was inadvertently removed.

**Assay methods**

Preoperative serum calcium, adjusted for serum albumin (reference range (RR), 8.6–10.2 mg/dl), alkaline phosphatase (RR, 40–129 U/l), and creatinine (RR, 0.5–1.2 mg/dl) were measured by auto-analyzer (Modular P 800: Roche Diagnostics). Plasma intact PTH (RR, 15–65 pg/ml) and 25-hydroxyvitamin D (RR, 11.1–42.9 ng/ml) levels were measured by electrochemiluminescence immunoassay (ELECSYS-2010, Roche Diagnostics) as per the manufacturer’s instructions.

**Histopathology**

After surgical excision, the specimens were weighed and fixed in 10% buffered formalin and embedded in paraffin for routine processing and paraffin blocking. A 3–5 \( \mu \text{m} \)-thick section was cut from each paraffin-embedded block stained with hematoxylin and eosin (H&E) and assessed by an expert parathyroid histopathologist (U N Saikia) to confirm the diagnosis of parathyroid adenoma as determined by an encapsulated tumor with very little fat associated with hypercellularity. Images were captured using a Leica DMR microscope (Leica, Germany) and a monochrome photometrics CCD camera (Photometrics, USA).

**Immunohistochemistry**

Representative paraffin blocks were retrieved and immunostained as previously reported (12, 22) and incubated with peroxidase-labeled secondary antibody (rabbit/mouse, Dako, Glostrup, Denmark). At a magnification of \( 20 \times \) and \( 40 \times \), \( \approx 500 \) cells were counted at four different locations for each section. Results were scored semiquantitatively based on percentage of positive cells and staining intensity. Detailed information on materials and methods for immunostaining are shown in Supplementary Table 1, see section on supplementary data given at the end of this article, and the scoring criteria for stain intensity of each antibody are in Supplementary Table 2.

**RNA extraction and cDNA synthesis**

Briefly, each tissue sample was crushed in 1 ml TRI reagent (Sigma–Aldrich). After chloroform addition, the aqueous and organic phases were separated by centrifugation. The aqueous (upper) phase was removed from each tube and transferred to a clean 1.5 ml microcentrifuge tube, where total RNA was precipitated by isopropanol. The RNA pellet was washed with 75% ethanol, allowed to dry, and dissolved in sterile water and stored at \(-20^\circ\text{C}\) until analysis. The 260:280 nm ratio of RNA (interval 1.9–2.1) was determined by Biophotometer plus (Eppendorf, Hamburg, Germany). The integrity was confirmed by denaturing gel electrophoresis, whereby sharp 28S and 18S bands were demonstrated. The cDNA was synthesized from 6 \( \mu \text{g} \) of total RNA by cDNA synthesis Kit (Fermentas, Life Sciences, Vilinus, Lithuania), according to the manufacturer’s protocol.

**Gene expression analysis**

The relative expression of VDR, CASR, CD1, and PTH in parathyroid adenoma cells was determined using quantitative real-time PCR (qRT-PCR) by SYBR Green I dye method (Fermentas, Life Sciences) on Light Cycler 480 Real-Time PCR System (Roche Diagnostics) as per the manufacturer’s recommendations. All samples were amplified in duplicate; non-template reactions were included as a negative control. Throughout qRT-PCR analysis, product identities were confirmed by melting curve analysis (Supplementary Figure 1, see section on supplementary data given at the end of this article).

Primers were designed using a web-based application (www.ncbi.nlm.nih.gov/tools/primer-blast/; Supplementary Table 3). All reactions were carried out in a 96-well optical reaction plate. A 1 \( \mu \text{l} \) volume of template cDNA (equivalent to 300 ng of total RNA) was added to 25 \( \mu \text{l} \) of PCR mixture containing 0.5 \( \mu \text{M} \) each forward and reverse primers. The pre-incubation was done at 95 °C for 10 min, followed by 50 cycles of PCR amplification (95 °C, 15 s; variable annealing temperature; 72 °C, 20 s), melting at 70 °C, for 1 min and final
step was extended to 10 min at 72°C. To confirm specificity of the primers, gel electrophoresis of the PCR products revealed one distinct band for each transcript. Finally, sequencing of the amplified product was performed (Applied Biosystems) to confirm the correct transcript. Amplification efficiencies of the targets and reference were found to be approximately equal. So analysis of the relative gene expression data was done by the 2^(-DDCt) method to produce the data as fold change up- or downregulation (27). In the fold change analysis, crossing point (Cp) value was determined as the number of cycles required for fluorescent signal to cross the threshold. The Cp values of both the calibrator (Control) and the sample of interest were normalized to the corresponding mean value of an endogenous housekeeping gene, GAPDH.

Statistical analyses

All analyses were performed using SPSS (10.01). The nonparametric Kolmogorov–Smirnov test was used to assess differences in all the study parameters between normal and adenomatous parathyroid samples. Values are presented as mean ± s.d. Mann–Whitney χ², and t-tests were performed as appropriate to compare the data between normal and adenomatous tissue. The Spearman’s ρ correlation test was applied for correlation analyses. The percentage of positive cells and staining intensity were compared using the Wilcoxon’s signed rank test. A P value of <0.05 was considered statistically significant.

Results

Clinical characteristics

Of the 55 consecutive patients who underwent parathyroidectomy during the study period, 41 patients (74.5%) had single adenomas, 12 (21.8%) had hyperplasia, and 2 (3.6%) had carcinoma. All the 41 parathyroid adenomas were included for detailed molecular studies. The mean age was 41.5 ± 13.3 years (range 11–67 years) with a male to female ratio of 1:3.2. The most common presenting manifestation was bone pain in 22 (52%) followed by renal stones in 17 (41%), fractures in 15 (36%), nephrocalcinosis and gall stones in 7 (17%) each, and pancreatitis in 5 (12%) patients. The relevant baseline biochemical measurements are shown in Table 1.

VDR expression

Thirteen (32%) of the parathyroid adenomas showed only cytoplasmic immunoreactivity for VDR while 26 (63%) showed both nuclear and cytoplasmic positivity and only 2 (5%) showed exclusive nuclear positivity. The mean proportion of adenomatous cells positive for VDR nuclear stain was 4% (median: 2%; range 0–40%) compared with 75% (median: 75; range 60–90%) in normal parathyroid tissue cells (P < 0.05, Fig. 1A). The mean proportion of adenomatous cells positive for cytoplasmic VDR stain was 29% (median: 30; range 0–70%) compared with 84% (median: 85; range 70–100%) in normal parathyroid cells (P < 0.05; Fig. 1A). Staining intensity was 1+ in 17 (42%), 2+ in 22 (54%), and 3+ in 1 (2%) adenomas and one adenoma (2%) had neither nuclear nor cytoplasmic positivity. All normal parathyroid cells showed 3+ staining intensity (Fig. 2), with a relative reduction in VDR expression of about 71% in nuclear and 55% in cytoplasmic stain (P < 0.05) in all the adenoma cells.

In qRT-PCR analysis, VDR mRNA expression was also reduced in 93% of adenoma cells with a fold change value of 0.36 ± 0.29 compared with normal parathyroid tissue cells (P < 0.001; Fig. 3A). The frequency of VDR under-expression was not correlated with indices of disease (albumin-adjusted calcium, intact PTH, 25-hydroxyvitamin D, or adenoma weight).

CASP R expression

All the parathyroid adenomas showed membranous positivity similar to normal parathyroid tissues, but the mean proportion of positive cells was 56.3 ± 15.9% compared with 78 ± 10.3% in normal parathyroid tissue cells (P < 0.05, Fig. 1B). Staining intensity was 1+ in 19 (46%), 2+ in 15 (37%), and 3+ in 7 (17%).

Table 1

Relevant biochemical measurements of the PHPT patients and controls. Data are expressed as mean (s.d.) and median.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Reference range</th>
<th>Adenoma (n=41)</th>
<th>Control (n=10)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corrected calcium (mg/dl)</td>
<td>8.6–10.2</td>
<td>12.1 ± 1.8 (11.7)</td>
<td>9.2 ± 0.4 (9.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/l)</td>
<td>40–129</td>
<td>336.0 ± 347.1 (238)</td>
<td>80.3 ± 29.3 (75.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.5–1.2</td>
<td>1.3 ± 1 (1)</td>
<td>0.9 ± 0.7 (0.7)</td>
<td>–</td>
</tr>
<tr>
<td>Intact PTH (pg/ml)</td>
<td>15–65</td>
<td>678.5 ± 727.7 (275)</td>
<td>24.5 ± 11.7 (21.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>25-Hydroxvitamin D (ng/ml)</td>
<td>11.1–42.9</td>
<td>24.5 ± 19.1 (19.4)</td>
<td>23.9 ± 8.4 (23.03)</td>
<td>0.5</td>
</tr>
<tr>
<td>Adenoma weight (g)</td>
<td></td>
<td>4.5±± 3.2; 3.29±± 3.2 (3.4)</td>
<td>0.5±± 0.1; 0.5±± 3.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*a Seven normal parathyroid glands obtained from patients undergoing euthyroid surgery and three from patients undergoing single parathyroid adenoma removal.

b From the three PHPT patients only.

Arithmetic mean.

Geometric mean.
adenomas. All the normal parathyroid tissue cells showed 3+ membranous positivity (Fig. 4).

The CASR mRNA expression was reduced in 90% of the adenoma cells with a mean fold change of $0.45 \pm 0.35$ compared with normal parathyroid tissue cells ($P<0.001$; Fig. 3A). There was no significant relationship of CASR mRNA expression to disease indices (corrected calcium, intact PTH, 25-hydroxyvitamin D, or adenoma weight).

CD1 expression

All the parathyroid adenomas showed cytoplasmic positivity, while normal parathyroid tissues showed intense nuclear as well as cytoplasmic positivity. The mean proportion of positive cells was $76.2 \pm 11.4\%$ compared with $66.5 \pm 13.1\%$ in normal parathyroid tissues ($P<0.05$; Fig. 1B). Stain intensity was 1+ in 18 (44%), 2+ in 14 (34%), and 3+ in 9 (22%) adenomas (Fig. 5). Normal parathyroid tissue samples showed 2+ to 3+ staining positivity for CD1.

The CD1 mRNA expression was increased in 85.4% of the adenomatous compared with normal parathyroid tissue cells with a mean fold change of $9.45 \pm 8.86$ ($P<0.001$; Fig. 3B). The frequency of CD1 overexpression was related to the adenoma weight ($r=0.715$; $P<0.001$; Fig. 6) but not with albumin-adjusted calcium, intact PTH, or 25-hydroxyvitamin D.

PTH expression

All the parathyroid adenoma cells showed diffuse cytoplasmic positivity in $83.3 \pm 10.2\%$ cells compared with $64.5 \pm 11.2\%$ of normal parathyroid tissues ($P<0.05$). Stain intensity was 1+ in 15 (37%), 2+ in 17 (41%), and 3+ in 9 (22%) adenomas. Staining intensity of PTH in normal parathyroid tissue samples was 2+ to 3+.

An increased expression of PTH mRNA was seen in all the parathyroid adenoma cells with variable fold change. The mean PTH mRNA fold change was $17.36 \pm 14.6$ (range 1.7–45.2 folds) in adenomatous compared with normal parathyroid tissue cells ($P<0.001$; Fig. 1B). In addition, the PTH analyses in the tissues served as ‘internal controls’, thus validating our other observations in this study. The PTH mRNA overexpression was related to intact PTH ($r=0.864$; $P<0.001$) but not with albumin-adjusted calcium, 25-hydroxyvitamin D, or adenoma weight.

Discussion

This is the comprehensive study of relevant candidate gene expressions in parathyroid adenomas with symptomatic PHPT, as commonly seen in India.

![Figure 1](image1.png)

Figure 1 Bar diagrams representing immunostaining-positive cells indicating (A) VDR expression in nucleus and cytoplasm and (B) CASR, CD1, and PTH expression in parathyroid normal and adenoma tissues respectively. All values are expressed as mean ± S.D., *$P<0.05$.

![Figure 2](image2.png)

Figure 2 Microphotographs showing localization of VDR expression in tissue sections of parathyroid gland. (1) Normal and (2, 3 and 4) represent intensity score in adenoma as 1+, 2+, and 3+ respectively. (2) Is in 10× and other figures are in 20× magnification. Full colour version of this figure available via http://dx.doi.org/10.1530/EJE-13-0085.
We found significantly reduced VDR and CASR and increased CD1 and PTH expressions in parathyroid adenomas compared with normal parathyroid tissue. In addition, we demonstrated a positive relationship between CD1 overexpression and adenoma weight. The major clinical manifestation in our patient group was bone pain and more than half of our patients had bone involvement. Our previous study (24) and a recent publication from China (28) have also shown that PHPT is still symptomatic with bone manifestations in this part of the world.

The downregulation of VDR expression in parathyroid adenomas in patients with symptomatic PHPT is similar to previous report of probably mild forms of PHPT (12, 14, 15, 16, 17, 18). Decreased CASR expression in parathyroid adenomas would be consistent with a less efficient control of PTH synthesis and secretion by calcium. The CASR gene has VDREs in the 5′-flanking region and is regulated by binding 1,25-dihydroxyvitamin D and VDR complex to VDREs (33, 34); thus, the reduction in CASR could be a consequence of reduced VDR. Previously, it has been suggested that reduced CASR expression could be the initiating event in parathyroid tumorigenesis (35). However, it seems more likely that CASR reduction is secondary to reduction in VDR expression as we found a greater magnitude of reduction in VDR compared with CASR expression. This could be explained by inhibition of gene transcription, less stable mRNA or post-translational modification, or gene silencing by hypermethylation in the promoter region as suggested by previous studies (12, 13, 18). It seems unlikely that hypercalcemia or elevated serum PTH, or adenomatous

staining (12). Nuclear localization of VDR with subsequent binding to vitamin D response elements (VDREs) in target genes is essential for vitamin D biological activity. The balance between the cellular compartments (nuclear/cytoplasmic) is probably relevant to the regulatory actions of vitamin D. More pronounced cytoplasmic VDR staining could indicate an ‘escape’ of parathyroid adenoma cells from homeostatic surveillance and growth control, especially if the regulatory mechanisms depended on ligand-activated receptor activity (29). Such alterations in cytoplasmic and nuclear VDR staining have also been reported in other neoplasms (30, 31, 32).

Reduced CASR expression was also found in adenomas compared with normal parathyroid tissue cells, and the magnitude of reduction was similar to previous reports on patients probably having mild forms of PHPT (12, 14, 15, 16, 17, 18). Decreased CASR expression in parathyroid adenomas would be consistent with a less efficient control of PTH synthesis and secretion by calcium. The CASR gene has VDREs in the 5′-flanking region and is regulated by binding 1,25-dihydroxyvitamin D and VDR complex to VDREs (33, 34); thus, the reduction in CASR could be a consequence of reduced VDR. Previously, it has been suggested that reduced CASR expression could be the initiating event in parathyroid tumorigenesis (35). However, it seems more likely that CASR reduction is secondary to reduction in VDR expression as we found a greater magnitude of reduction in VDR compared with CASR expression. This could be explained by inhibition of gene transcription, less stable mRNA or post-translational modification, or gene silencing by hypermethylation in the promoter region as suggested by previous studies (12, 13, 18). It seems unlikely that hypercalcemia or elevated serum PTH, or adenomatous

staining (12). Nuclear localization of VDR with subsequent binding to vitamin D response elements (VDREs) in target genes is essential for vitamin D biological activity. The balance between the cellular compartments (nuclear/cytoplasmic) is probably relevant to the regulatory actions of vitamin D. More pronounced cytoplasmic VDR staining could indicate an ‘escape’ of parathyroid adenoma cells from homeostatic surveillance and growth control, especially if the regulatory mechanisms depended on ligand-activated receptor activity (29). Such alterations in cytoplasmic and nuclear VDR staining have also been reported in other neoplasms (30, 31, 32).

Reduced CASR expression was also found in adenomas compared with normal parathyroid tissue cells, and the magnitude of reduction was similar to previous reports on patients probably having mild forms of PHPT (12, 14, 15, 16, 17, 18). Decreased CASR expression in parathyroid adenomas would be consistent with a less efficient control of PTH synthesis and secretion by calcium. The CASR gene has VDREs in the 5′-flanking region and is regulated by binding 1,25-dihydroxyvitamin D and VDR complex to VDREs (33, 34); thus, the reduction in CASR could be a consequence of reduced VDR. Previously, it has been suggested that reduced CASR expression could be the initiating event in parathyroid tumorigenesis (35). However, it seems more likely that CASR reduction is secondary to reduction in VDR expression as we found a greater magnitude of reduction in VDR compared with CASR expression. This could be explained by inhibition of gene transcription, less stable mRNA or post-translational modification, or gene silencing by hypermethylation in the promoter region as suggested by previous studies (12, 13, 18). It seems unlikely that hypercalcemia or elevated serum PTH, or adenomatous

staining (12). Nuclear localization of VDR with subsequent binding to vitamin D response elements (VDREs) in target genes is essential for vitamin D biological activity. The balance between the cellular compartments (nuclear/cytoplasmic) is probably relevant to the regulatory actions of vitamin D. More pronounced cytoplasmic VDR staining could indicate an ‘escape’ of parathyroid adenoma cells from homeostatic surveillance and growth control, especially if the regulatory mechanisms depended on ligand-activated receptor activity (29). Such alterations in cytoplasmic and nuclear VDR staining have also been reported in other neoplasms (30, 31, 32).

Reduced CASR expression was also found in adenomas compared with normal parathyroid tissue cells, and the magnitude of reduction was similar to previous reports on patients probably having mild forms of PHPT (12, 14, 15, 16, 17, 18). Decreased CASR expression in parathyroid adenomas would be consistent with a less efficient control of PTH synthesis and secretion by calcium. The CASR gene has VDREs in the 5′-flanking region and is regulated by binding 1,25-dihydroxyvitamin D and VDR complex to VDREs (33, 34); thus, the reduction in CASR could be a consequence of reduced VDR. Previously, it has been suggested that reduced CASR expression could be the initiating event in parathyroid tumorigenesis (35). However, it seems more likely that CASR reduction is secondary to reduction in VDR expression as we found a greater magnitude of reduction in VDR compared with CASR expression. This could be explained by inhibition of gene transcription, less stable mRNA or post-translational modification, or gene silencing by hypermethylation in the promoter region as suggested by previous studies (12, 13, 18). It seems unlikely that hypercalcemia or elevated serum PTH, or adenomatous

staining (12). Nuclear localization of VDR with subsequent binding to vitamin D response elements (VDREs) in target genes is essential for vitamin D biological activity. The balance between the cellular compartments (nuclear/cytoplasmic) is probably relevant to the regulatory actions of vitamin D. More pronounced cytoplasmic VDR staining could indicate an ‘escape’ of parathyroid adenoma cells from homeostatic surveillance and growth control, especially if the regulatory mechanisms depended on ligand-activated receptor activity (29). Such alterations in cytoplasmic and nuclear VDR staining have also been reported in other neoplasms (30, 31, 32).

Reduced CASR expression was also found in adenomas compared with normal parathyroid tissue cells, and the magnitude of reduction was similar to previous reports on patients probably having mild forms of PHPT (12, 14, 15, 16, 17, 18). Decreased CASR expression in parathyroid adenomas would be consistent with a less efficient control of PTH synthesis and secretion by calcium. The CASR gene has VDREs in the 5′-flanking region and is regulated by binding 1,25-dihydroxyvitamin D and VDR complex to VDREs (33, 34); thus, the reduction in CASR could be a consequence of reduced VDR. Previously, it has been suggested that reduced CASR expression could be the initiating event in parathyroid tumorigenesis (35). However, it seems more likely that CASR reduction is secondary to reduction in VDR expression as we found a greater magnitude of reduction in VDR compared with CASR expression. This could be explained by inhibition of gene transcription, less stable mRNA or post-translational modification, or gene silencing by hypermethylation in the promoter region as suggested by previous studies (12, 13, 18). It seems unlikely that hypercalcemia or elevated serum PTH, or adenomatous

staining (12). Nuclear localization of VDR with subsequent binding to vitamin D response elements (VDREs) in target genes is essential for vitamin D biological activity. The balance between the cellular compartments (nuclear/cytoplasmic) is probably relevant to the regulatory actions of vitamin D. More pronounced cytoplasmic VDR staining could indicate an ‘escape’ of parathyroid adenoma cells from homeostatic surveillance and growth control, especially if the regulatory mechanisms depended on ligand-activated receptor activity (29). Such alterations in cytoplasmic and nuclear VDR staining have also been reported in other neoplasms (30, 31, 32).

Reduced CASR expression was also found in adenomas compared with normal parathyroid tissue cells, and the magnitude of reduction was similar to previous reports on patients probably having mild forms of PHPT (12, 14, 15, 16, 17, 18). Decreased CASR expression in parathyroid adenomas would be consistent with a less efficient control of PTH synthesis and secretion by calcium. The CASR gene has VDREs in the 5′-flanking region and is regulated by binding 1,25-dihydroxyvitamin D and VDR complex to VDREs (33, 34); thus, the reduction in CASR could be a consequence of reduced VDR. Previously, it has been suggested that reduced CASR expression could be the initiating event in parathyroid tumorigenesis (35). However, it seems more likely that CASR reduction is secondary to reduction in VDR expression as we found a greater magnitude of reduction in VDR compared with CASR expression. This could be explained by inhibition of gene transcription, less stable mRNA or post-translational modification, or gene silencing by hypermethylation in the promoter region as suggested by previous studies (12, 13, 18). It seems unlikely that hypercalcemia or elevated serum PTH, or adenomatous
transformation itself due to increased proliferative activity, is responsible for VDR and CASR downregulation (12, 13, 18) as we found no correlation between adenoma weight and preoperative serum calcium, PTH, or 25-hydroxyvitamin D levels in our patients.

Interestingly, CD1 immunostaining was seen exclusively in the cytoplasm in all the samples without nuclear staining. In contrast, previous studies have observed both nuclear, and to a lesser degree, cytoplasmic staining (19, 20, 21, 22, 23). Overexpression of CD1 both in nuclear and in cytoplasmic compartments has been reported in many human malignancies. CD1 plays an important role in proliferation and differentiation, and a shift between nucleus and cytoplasm is necessary to regulate smooth passage across different phases of the cell cycle. Cytoplasmic staining for CD1 occurs during G1 to S transition of the cell cycle, while nuclear staining is visualized only in G1 phase (36). CD1 expression is lowest during S phase (37), perhaps explaining why we observed low intensities of CD1 in most of the adenomas comparing to normal parathyroid tissue.

We found overexpression of CD1 mRNA in 85% of the parathyroid adenomas in comparison to 20–40% reported previously (19, 20, 21, 22, 23). Of the four genes (VDR, CASR, CD1, and PTH) analyzed in this study, only CD1 expression was significantly associated with parathyroid adenoma weight. Also, the increase in CD1 expression was numerically related to PTH level but did not quite reach statistical significance. This rather robust overexpression of CD1 could conceivably be related to the larger tumors, higher PTH levels, and more severe clinical expression of the disease in this part of the world. As we did not systematically examine the ‘upstream’ gene expressions (as was reported in a previous study (22)) either in this or our previous study (12), the potential role of overexpression of CD1 in parathyroid adenoma size or differential expression of the disease requires further investigation.

There were certain limitations such as relatively small sample size, lack of comparable data from patients with mild PHPT, a phenotype rarely seen in India, smaller number of normal parathyroid tissue (n = 10), and our inability to measure serum 1,25-dihydroxyvitamin D levels for lack of resources. Nevertheless, the strength of our study is the simultaneous analysis of four relevant genes and demonstration of a similar magnitude of reductions in VDR and CASR in moderate severe PHPT just as in the cases reported to be probably having mild form of PHPT (12). Our study results also suggest that the mechanisms underlying parathyroid tumorigenesis and their growth behavior are probably different.

In conclusion, we have demonstrated reduced VDR and CASR expression and increased CD1 and PTH by immunohistochemistry and confirmed with the respective mRNA analyses in parathyroid adenomas. In addition, we found that overexpression of CD1 correlated with the weight of parathyroid adenoma. Further investigations of the pathway of these genes with larger sample size could help better understand the pathogenesis and progression of disease in patients with severe PHPT and unravel potential new therapeutic targets.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-13-0085.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was partially supported by a grant from the Indian Council of Medical Research (ICMR), New Delhi India (IRIS ID no. 2009-044680).
Molecular mechanisms in the pathogenesis of PHPT


www.eje-online.org

Acknowledgements

The authors thank Dr Rajesh Khadagwats, Additional Professor, Department of Endocrinology, All India Institute of Medical Sciences (AIIMS), New Delhi, and Dr K Rajagopal from the Institute of Microbial Technology (IMTECH), Chandigarh, for their helpful discussions.


37 Hitomi M & Stacey DW. Cellular ras and cyclin D1 are required during different cell cycle periods in cycling NIH 3T3 cells. *Molecular and Cellular Biology* 1999 19 4623–4632.

Received 28 January 2013
Revised version received 19 April 2013
Accepted 9 May 2013